Article citationsMore>>

Ambrosini, M., Blons, H., Garinet, S., Mulot, C., Le Corre, D., Mouillet-Richard, S., et al. (2025) Negative Hyperselection of Patients with Stage III Colon Cancer Receiving Anti-EGFR-Based Adjuvant Treatment. ESMO Open, 10, Article 105857.
https://doi.org/10.1016/j.esmoop.2025.105857

has been cited by the following article:

• TITLE: Beyond TNM Staging: Clinical Significance of Combined Molecular Biomarkers (TP53, Ki67, RAS, and MSI) in Colorectal Cancer

  AUTHORS: Taiyan Zhu

  KEYWORDS: Colorectal Cancer, Precision Medicine, TP53, KRAS, Microsatellite Instability, Ki67, Risk Stratification

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.14 No.5, May 7, 2026

  ABSTRACT: Current colorectal cancer management relies on TNM staging and single-gene testing, often failing to capture biological heterogeneity. This study evaluates the synergistic prognostic value of TP53, Ki67, RAS, and MSI in a 120-patient cohort. We identify a high-risk “Triple Hit” phenotype (MSS/RAS-mut/TP53-mut/High-Ki67) that independently predicts poor overall survival, particularly demonstrating significant risk stratification within early-stage disease. Our proposed Combined Molecular Score offers superior prognostic resolution compared to TNM staging alone. This accessible multi-dimensional atlas provides a robust tool for risk assessment, bridging the gap between molecular biology and routine clinical practice while providing a hypothesis-generating framework for future therapeutic intensification.